Oral golidocitinib for newly diagnosed peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a new diagnosis of peripheral T-cell lymphoma (a type of non-Hodgkin lymphoma) — and not have received any previous treatment for it.
- Your lymphoma must be one of these specific subtypes: PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, or PTCL with TFH phenotype.
- You must have at least one tumor that can be measured on scans (measurable disease).
- Your overall health should be fairly good (able to manage daily activities with minimal or no help).
- You cannot have active infections, recent blood clots, serious heart problems, or a history of lung disease that required steroids.
- You must be able to swallow pills and be willing to use effective birth control during the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a combination of two drugs, chidamide and golidocitinib, for peripheral T-cell lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests whether a daily pill called golidocitinib can keep your PTCL from coming back after you've had a good response to your first chemotherapy. The study compares the drug to a placebo (a pill with no active medicine) to see if it helps prevent relapse.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.